The rising incidence of cancer is one of the significant factors influencing the oncology molecular diagnostics market growth.
Market Size – USD 1,456.6 Million in 2019, Market Growth – CAGR of 11.8%, Market Trends –Increasing awareness about cancer diagnosis at an early stage.
The global Oncology Molecular Diagnostics Market is forecasted to reach USD 3,568.1 Million by 2027, according to a new report by Reports and Data. The oncology molecular diagnostics market is observing high growth due to the rising occurrences of breast cancer across the globe. Breast cancer is the most common type of cancer occurring in women. There were more than 2 million new cases of breast cancer in 2018. Belgium, Luxembourg, and the Netherlands are the countries with the highest rates of occurrences of breast cancer in the year 2018 across the globe. The global survival rates from the disease vary greatly, ranging from around 80% in North America, Japan, and Sweden to nearby 60% in middle-income nations and lower than 40% in low-income nations. Hence, the implementation of molecular breast diagnostics to screen and detect malignant cells in the human breast is driving the growth of the oncology molecular diagnostics market.
The COVID-19 impact:
The COVID-19 pandemic has made it essential to repurpose the operating rooms for surgeries into intensive care units (ICUs) and pushed hospitals to accommodate patients beyond their full capacity of beds. As a result, in several cases, cancer patients were categorized as non-urgent. Further, the psychological influence of postponed cancer diagnosis as a result of the COVID-19 pandemic cannot be undermined as when psychological, physical, and social health of patients are handled in a positive way, chances of patients’ survival have been seen to improve from a state of illness towards recovering from the disease. COVID-19 has had a significant and negative impact on cancer treatment and research, making a new health emergency for cancer patients’ management a necessity.
Key participants include Becton, Dickinson, and Company, Danaher Corporation, Roche Diagnostics, Abbott Laboratories, Cepheid, Qiagen NV, Siemens Healthineers, Bayer AG, Dako, and GE Healthcare, among others.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3714
Further key findings from the report suggest
- Cervical cancer is a significant driver of oncology molecular diagnostics market growth as it is one most common causes of cancer in women, with over 500,000 new cases taking place per year across the globe.
- PCR held a significant market share in 2019, as a real-time PCR offers benefits such as greater sensitivity, quantification ease, precision & reproducibility, better process quality, fast analysis, and lower contamination risk.
- Hospitals dominated the oncology molecular diagnostics s market in 2019. The factors including well-resourced operating & diagnostic rooms, higher purchasing power, the existence of highly skilled healthcare professionals, and improved health coverage for hospital-based healthcare services from several private and group insurance plans, among others, are responsible for the high market share of hospitals.
- North America contributed to the largest oncology molecular diagnostics market share in 2019. The market dominance is owing to the higher acceptance of advanced technologies, well-established healthcare diagnostic facilities, the surging incidence of cancer, and the enactment of numerous initiatives for raising awareness about the disease in the region.
To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/oncology-molecular-diagnostics-market
For the purpose of this report, Reports and Data has segmented into the global oncology molecular diagnostics market on the basis of cancer type, component, technology, end-user, and region:
Cancer Type Outlook (Revenue, USD Million; 2017-2027)
- Breast Cancer
- Prostate Cancer
- Cervical Cancer
- Colorectal Cancer
- Lung Cancer
- Blood Cancer
- Liver Cancer
- Kidney Cancer
Component Outlook (Revenue, USD Million; 2017-2027)
- Instruments
- Reagents
- Others
Technology Outlook (Revenue, USD Million; 2017-2027)
- In Situ Hybridization
- PCR
- Isothermal Nucleic Acid Amplification Technology
- Mass Spectrometry
- Others
End-User Outlook (Revenue, USD Million; 2017-2027)
- Hospitals and Clinics
- Diagnostic Centers
- Others
Regional Outlook (Revenue, USD Million; 2017-2027)
- North America
- Europe
- Asia Pacific
- MEA
- Latin America
Order Now: @ https://www.reportsanddata.com/checkout-form/3714
Chapter 1. Market Synopsis
1.1. Market Definition
1.2. Research Scope & Premise
1.3. Methodology
1.4. Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Indicative Metrics
Chapter 4. Oncology Molecular Diagnostics Market Segmentation & Impact Analysis
4.1. Oncology Molecular Diagnostics Market Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
4.2.2.1. Rising incidence of cancer
4.2.2.2. Increasing awareness about early disease diagnosis
4.2.2.3. Growing demand for point of care treatment
4.2.2.4. Growing geriatric population
4.2.3. Market restraints analysis
4.2.3.1. Cost prohibitive molecular diagnostic test
4.3. Technological Insights
4.4. Regulatory Framework
4.5. ETOP Analysis
4.6. Porter’s Five Forces Analysis
4.7. Competitive Metric Space Analysis
4.8. Price trend Analysis
4.9. Customer Mapping
4.10. Covid-19 Impact Analysis
4.11. Global Recession Influence
….
Chapter 10. Competitive Landscape
10.1. Market Revenue Share By Manufacturers
10.2. Manufacturing Cost Breakdown Analysis
10.3. Mergers & Acquisitions
10.4. Market positioning
10.5. Strategy Benchmarking
10.6. Vendor Landscape
Chapter 11. Company Profiles
11.1. Becton, Dickinson, and Company
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Technology Insights
11.1.4. Strategic Initiatives
11.2. Danaher Corporation
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Technology Insights
11.2.4. Strategic Initiatives
11.3. Roche Diagnostics
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Technology Insights
11.3.4. Strategic Initiatives
11.4. Abbott Laboratories
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Technology Insights
11.4.4. Strategic Initiatives
11.5. Cepheid
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Technology Insights
11.5.4. Strategic Initiatives
Continue….
Thank you for reading our report. For further query on the report and customization, please connect with us. Our team will ensure you get the report best suited for your needs.
About Us:
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.
Media Contact
Company Name: Reports and Data
Contact Person: John Watson
Email: Send Email
Phone: +1-212-710-1370
Address:40 Wall St. 28th floor
City: New York City
State: NY 10005
Country: United States
Website: https://www.reportsanddata.com/press-release/global-oncology-molecular-diagnostics-market